RAF1 and cancer: However, they can bind both protomers of RAF dimer with equal potency and inhibit ERK signaling in RAS mutant cells.432–437 RAF dimer inhibitors have been reported to inhibit RAS mutant tumors in preclinical models, and several of them have been associated with partial responses in RAS-mutant cancer patients in phase I clinical trials.